We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Hydrogel-Based Technology Isolates Extracellular Vesicles for Early Disease Diagnosis

By LabMedica International staff writers
Posted on 18 Nov 2025

Isolating extracellular vesicles (EVs) from biological fluids is essential for early diagnosis, therapeutic development, and precision medicine. More...

However, traditional EV-isolation methods rely on ultracentrifugation, which requires expensive equipment, complex preprocessing, and low throughput — barriers that limit broader clinical and industrial use. Researchers have now developed a frozen-hydrogel technology that rapidly isolates EVs from multiple biofluids without specialized instruments.

The technology was developed by researchers at Korea University (Seoul, South Korea) and the Korea Institute of Science and Technology (KIST, Seoul, South Korea) by freezing a hydrogel material and curing it with light, forming a three-dimensional microporous network with pore sizes of about 400 nanometers — a structure previously considered unattainable. This porous hydrogel selectively captures permeable EVs while allowing other components to pass through, enabling efficient isolation without pretreatment.

The approach eliminates the need for ultracentrifugation and works on a wide range of biofluids. In their study, the hydrogel isolated EVs rapidly from blood, urine, saliva, milk, cell culture media, and ascites from gastric cancer patients. The method was validated as a high-efficiency, accessible, and easy-to-use solution that does not require costly machinery or operator training. The results, published in Nature Nanotechnology, suggest that the technology can reliably obtain high-purity EVs suitable for diagnostic and therapeutic applications.

Practical applications include early disease detection, monitoring, and personalized treatment across cancer, neurodegenerative disorders, and metabolic diseases. The ease of use and scalability also position the platform to support major bioindustry sectors such as precision medicine, new drug development, and in vitro diagnostics.

“In the future, researchers and companies will be able to obtain high-purity EVs through a simple process that does not require complex equipment or training, and the new technology will provide a practical foundation for a range of high-value-added bioindustries,” said Korea University Professor Choi Nak-won, PhD.

“Our new technology has overcome the major limitations of the existing EV isolation methods, and we have demonstrated that the new technology has advantages in terms of its efficiency, accessibility, mass processing and user customization,” added KIST senior researcher Kang Ji-yoon, PhD.

Related Links:
Korea University
KIST 


New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Test
Allplex HPV28 Detection
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.